MK-677 (Ibutamoren) and Hormonal Contraceptives: What the Science Actually Shows

What Is MK-677 and Why Does It Interact With Hormones?

MK-677 (ibutamoren) is a selective, orally active agonist of the ghrelin receptor (GHSR-1a). Unlike injectable growth hormone, it stimulates the pituitary to release GH in natural pulses. Those GH pulses then drive hepatic IGF-1 production. In the landmark 2-year trial by Nass et al. (N=65 older adults), oral MK-677 25 mg daily raised IGF-1 by roughly 40% above baseline and sustained that elevation throughout the study period 1.

Ghrelin Receptor Pharmacology

Ghrelin receptors are expressed in the hypothalamus, pituitary, and peripheral tissues including the liver and reproductive organs. MK-677 binding to GHSR-1a in the pituitary amplifies GH pulse amplitude without suppressing endogenous GH secretion. This distinguishes it mechanistically from exogenous recombinant GH 2.

Why the Hormonal Axis Matters

GH and IGF-1 are not metabolically neutral bystanders. They modulate hepatic protein synthesis, including SHBG, which is the primary carrier protein for estradiol and testosterone in plasma. When IGF-1 rises, hepatic SHBG synthesis tends to fall. That shift increases the free (biologically active) fractions of both endogenous and exogenous sex steroids. The direction is predictable; the magnitude in any individual using a specific contraceptive formulation is not.

CYP3A4 and Pharmacokinetic Interactions

Hormonal contraceptives and MK-677 share metabolic territory in the liver. Understanding that overlap requires looking at each drug's CYP profile.

How Hormonal Contraceptives Are Metabolized

Ethinyl estradiol (EE), the estrogen component of most combined oral contraceptives (COCs), is primarily metabolized by CYP3A4, with secondary involvement of CYP2C9 and phase-II glucuronidation 3. Most synthetic progestins, including levonorgestrel, norethindrone, norgestimate, and etonogestrel, are also CYP3A4 substrates to varying degrees. Drospirenone is additionally metabolized by CYP3A4 and has mild mineralocorticoid receptor activity, adding another layer of interaction potential.

MK-677's Metabolic Footprint

MK-677 is metabolized hepatically, with CYP3A4 contributing to its clearance. In vitro data from Merck's original pharmacokinetic characterization indicated that the compound is a moderate CYP3A4 substrate 4. Competitive inhibition at the enzyme level is possible when two CYP3A4 substrates are co-administered, though the clinical magnitude depends on the relative Km values and administered doses of each drug. MK-677 does not appear to be a strong CYP3A4 inhibitor at typical research doses of 10 to 25 mg, so outright contraceptive failure from enzyme inhibition alone is unlikely. Still, exposure changes of 10 to 30% in EE or progestin AUC could have clinical relevance for women with conditions sensitive to hormone fluctuation.

P-glycoprotein Considerations

P-glycoprotein (P-gp) is a drug efflux transporter encoded by ABCB1. Several progestins, including progesterone and some synthetic analogs, are P-gp substrates. MK-677 has structural features of a P-gp substrate as well. Co-administration could theoretically reduce efflux of either compound from enterocytes, increasing oral bioavailability. No published clinical data quantify this interaction specifically for MK-677 and oral contraceptives. This remains a theoretical concern rather than a documented effect.

IGF-1, SHBG, and Free Hormone Exposure

This is the more clinically significant interaction pathway. The pharmacodynamic (PD) interplay between elevated IGF-1 and sex hormone-binding globulin is better characterized in the endocrine literature than the CYP overlap.

How IGF-1 Suppresses SHBG

Hepatocytes synthesize SHBG under the influence of estrogen (which raises it) and insulin/IGF-1 (which lower it). GH excess, as seen in acromegaly, consistently lowers SHBG 5. MK-677 produces a more modest and controlled GH rise than pathological GH excess, but the directional effect on SHBG is the same. A study by Murphy et al. Examining GH administration in 30 postmenopausal women found SHBG decreased by approximately 25% over 12 weeks of GH therapy 6.

Practical Consequence for Contraceptive Users

When SHBG falls, free estradiol and free progestin fractions rise even without a change in total hormone dose. For a woman on a 20 mcg EE pill who starts MK-677 25 mg daily, the effective free EE exposure could increase meaningfully. Side effects associated with higher free estrogen include breast tenderness, nausea, breakthrough spotting, and, at the serious end, an increased risk of venous thromboembolism (VTE). The baseline VTE risk with combined oral contraceptives is already approximately 3 to 9 per 10,000 woman-years compared with 1 to 5 per 10,000 in non-users, as documented in a large pharmacoepidemiological study published in the BMJ 7.

Progestin-Only Methods and IUDs

Progestin-only pills, the levonorgestrel IUD (Mirena), and the etonogestrel implant (Nexplanon) have different risk profiles. Because they contain no estrogen, the VTE concern is substantially lower. However, free progestin elevation from SHBG suppression could theoretically intensify progestogenic side effects such as mood changes, acne, and irregular bleeding. The levonorgestrel IUD releases hormone locally into the uterine cavity; systemic absorption is low (roughly 20 mcg/day), which may limit the clinical significance of SHBG changes for IUD users specifically.

Severity Assessment and Clinical Classification

No standard DDI database (Drugs.com, Lexicomp, Micromedex) currently lists a formal interaction between MK-677 and hormonal contraceptives, primarily because MK-677 lacks FDA approval and has no label. The interaction must be classified using mechanistic inference. A practical severity framework for clinical use:

| Interaction Pathway | Mechanism | Estimated Severity | Evidence Quality | |---|---|---|---| | CYP3A4 substrate competition | PK | Mild-to-moderate | Preclinical / in vitro | | SHBG suppression via IGF-1 | PD | Moderate | Indirect clinical (GH studies) | | P-gp efflux competition | PK | Mild (theoretical) | Theoretical | | VTE risk amplification (COC users) | PD | Potentially serious | Inferential |

The highest-priority concern is VTE risk amplification in women already using combined hormonal contraceptives (CHCs), particularly those with additional VTE risk factors such as obesity, smoking, factor V Leiden mutation, or prolonged immobility.

What Guidelines and Regulators Say

No published guideline from the Endocrine Society, the American College of Obstetricians and Gynecologists (ACOG), or the FDA directly addresses MK-677 co-administration with hormonal contraceptives. That absence of guidance is itself informative: MK-677 is not approved, and regulatory bodies do not issue interaction guidance for unapproved research chemicals used outside clinical trials.

FDA Stance on MK-677

The FDA has not approved ibutamoren for any indication. The agency has issued warning letters to companies marketing MK-677 as a dietary supplement, noting that the compound does not meet the legal definition of a dietary ingredient 8. Physicians who encounter patients using MK-677 should document it as an unapproved substance in the medical record.

ACOG on Hormonal Contraceptive Drug Interactions

ACOG Practice Bulletin 206 states that "clinicians should be aware that drugs that induce or inhibit CYP3A4 may alter the pharmacokinetics of combined hormonal contraceptives and potentially affect efficacy or side-effect profiles" 9. While this bulletin does not name MK-677, the principle directly applies to the CYP3A4 overlap described above.

Patient Counseling Points

Women who disclose MK-677 use to their clinician while on hormonal contraceptives need clear, specific guidance rather than a blanket prohibition. The conversation should cover several concrete points.

Disclosure and Documentation

Every supplement and research chemical a patient uses should be documented in the medication list. MK-677 should be entered under "other substances: unapproved research chemical (ibutamoren/MK-677), dose, frequency." This protects both the patient and the clinician.

Contraceptive Method Selection

For women who want to continue MK-677 for research or personal use, progestin-only methods or non-hormonal options (copper IUD, barrier methods) carry fewer theoretical interaction concerns than combined hormonal methods. The copper IUD is 99.2% effective at 12 years without any hormonal substrate for CYP or SHBG interactions 10.

Symptom Monitoring

Women continuing combined hormonal contraceptives alongside MK-677 should report new or worsening breast tenderness, unscheduled bleeding, calf pain or swelling, or shortness of breath. These symptoms could indicate altered free-hormone exposure or, in the case of leg or chest symptoms, early VTE.

Lab Monitoring Protocol

Baseline labs before starting MK-677 should include IGF-1, SHBG, free estradiol (if on a CHC), fasting glucose, and a basic metabolic panel. MK-677 raises fasting blood glucose by inducing mild insulin resistance; the Nass 2-year trial found fasting glucose increased by 0.3 mmol/L and insulin resistance (by HOMA-IR) rose significantly in the treated group 1. Repeat IGF-1 and SHBG at 6 to 8 weeks after starting MK-677 gives a functional picture of the degree of SHBG suppression in that individual.

Special Populations and Risk Stratification

Women With PCOS

Polycystic ovary syndrome (PCOS) already involves elevated IGF-1 sensitivity, reduced SHBG, and hyperandrogenism. Adding MK-677 to this background could worsen free androgen excess. For PCOS patients on combined oral contraceptives specifically to raise SHBG and reduce free androgens, MK-677 directly opposes the therapeutic goal. The 2023 international PCOS evidence-based guideline states that SHBG measurement is a key marker of hyperandrogenism severity 11.

Perimenopausal Women

Perimenopausal women sometimes use MHT (menopausal hormone therapy) rather than contraceptives. The same SHBG and CYP3A4 considerations apply. For women using transdermal estradiol rather than oral EE, first-pass CYP3A4 interaction is less relevant, making transdermal routes potentially safer in this context.

Adolescents

MK-677 is particularly concerning in adolescents. GH pulse manipulation during active epiphyseal growth carries risks of disproportionate skeletal changes. Combined with hormonal contraceptives that themselves affect bone mineral density, the risks are compounded. Use in adolescents should be strongly discouraged pending any human safety data from controlled trials 12.

Absence of Dedicated Interaction Trials

No published randomized controlled trial has examined MK-677 co-administration with any hormonal contraceptive formulation. The research that does exist on MK-677 in humans is limited to a handful of trials:

• Nass et al. (2008, N=65): 2-year trial in older adults; established IGF-1 elevation and glucose effects 1.
• Copinschi et al. (1997, N=32): Short-term MK-677 in young and elderly adults; characterized GH pulse augmentation 2.
• Murphy et al. (2001, N=30): GH administration in postmenopausal women; documented SHBG suppression of approximately 25% 6.

None of these trials enrolled women of reproductive age concurrently using hormonal contraceptives. The interaction guidance in this article is therefore extrapolated from mechanism and adjacent clinical evidence rather than direct trial data. That limitation should be communicated explicitly to patients.

Summary of Monitoring Protocol

The following lab and symptom schedule offers a practical approach for the rare clinical scenario where a patient insists on continuing both MK-677 and hormonal contraceptives after counseling.

Before starting MK-677:

• IGF-1 (serum)
• SHBG (serum)
• Free estradiol (if on CHC)
• Fasting glucose and insulin (calculate HOMA-IR)
• Blood pressure

At 6 to 8 weeks:

• Repeat IGF-1 and SHBG
• Patient-reported symptom review (bleeding pattern, breast tenderness, mood)
• Fasting glucose

At 6 months:

• Full repeat of baseline panel
• Reassess contraceptive method appropriateness
• Document any adverse events

If SHBG has fallen by more than 30% from baseline, a frank discussion about switching to a non-hormonal or progestin-only contraceptive method is warranted, as free hormone fractions will have increased substantially.